Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A case records based retrospectively study for the clinical efficacy of cetuximab maintenance therapy in KRAS wild metastatic colorectal carcinoma

ABSTRACT: Interventions: Case series:cetuximab maintenance Primary outcome(s): PFS Study Design: Non randomized control

DISEASE(S): Colorectal Cancer

PROVIDER: 2687280 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Feasibility and safety study of apatinib mesylate in combination with s-1 for neoadjuvant treatment of colorectal cancer and postoperative management of s-1

Project description:Interventions: Case series:Preoperative apatinib combined with S-1, for the maintenance of postoperative S-1 Primary outcome(s): Total resection rate (R0 / R1 / R2);Two-year disease-free survival rate;Safty;PFS;PFS Study Design: Case series

| 2675770 | ecrin-mdr-crc

Leishmania case

Project description:Leishmania case

| PRJEB71936 | ENA

A open-lable,single arm and exploratory clinical trail of Apatinib for first-line Maintenance treatment of advanced colorectal cancer.

Project description:Interventions: Apatinib treatment group:Apatinib Tablets orally Primary outcome(s): PFS;ORR Study Design: Case series

| 2670828 | ecrin-mdr-crc

Case study: Neonatal Meningitis

Project description:A case study of a neonatal meningitis case

| PRJEB81278 | ENA

High throughput screening identifies SOX2 as a Super Pioneer Factor that inhibits DNA methylation maintenance at its binding sites

Project description:Access of mammalian transcription factors (TFs) to regulatory regions, an essential event for transcription regulation, is hindered by chromatin compaction involving nucleosome wrapping, repressive histone modifications and DNA methylation. Moreover, methylation of TF binding sites (TBSs) affects TF binding affinity to these sites. Remarkably, a special class of TFs called pioneer transcription factors (PFs) can access nucleosomal DNA, leading to nucleosome remodelling and chromatin opening. However, whether PFs can bind to methylated sites and induce DNA demethylation is largely unknown. Here, we set up a highly parallelized approach to investigate PF ability to bind methylated DNA and induce demethylation. Our results indicate that the interdependence between DNA methylation and TF binding is more complex than previously thought, even within a select group of TFs that have a strong pioneering activity; while most PFs do not induce changes in DNA methylation at their binding sites, we identified PFs that can protect DNA from methylation and PFs that can induce DNA demethylation at methylated binding sites. We called the latter “super pioneer transcription factors” (SPFs), as they are seemingly able to overcome several types of repressive epigenetic marks. Importantly, while most SPFs induce TET-dependent active DNA demethylation, SOX2 binding leads to passive demethylation by inhibition of the maintenance methyltransferase DNMT1 during replication. This important finding suggests a novel mechanism allowing TFs to interfere with the epigenetic memory during DNA replication.

2021-03-18 | GSE144524 | GEO

S Bovismorbificans, domestic case

Project description:S Bovismorbificans, domestic case

| PRJEB26994 | ENA

Salmonella Bovismorbificans domestic case

Project description:Salmonella Bovismorbificans domestic case

| PRJEB26991 | ENA

Project description:cefepime-zidebactam case series

| PRJNA1174875 | ENA

Avastin and chemotherapy followed by a KRAS stratified randomization to maintenance treatment for first line treatment of metastatic colorectal cancer

Project description:Primary objectives: To demonstrate that maintenance treatment with bevacizumab + erlotinib following first line chemo- and anti-angiogenetic therapy results in a significant increase in progression-free survival (PFS) rate at 3 months among patients without KRAS mutation as compared to maintenance treatment with bevacizumab alone. Primary endpoints: To evaluate maintenance treatment with bevacizumab+erlotinib versus bevacizumab alone in patients with KRAS WT tumors following first line chemo- and anti-angiogenetic therapy by comparing progression-free survival rate at 3 months.

| 2528060 | ecrin-mdr-crc

A single center and single arm study for personalized neoantigen peptides vaccine in the treatment of advanced colorectal cancer

Project description:Interventions: Case series:Case series Primary outcome(s): Safety Index;ORR;PFS;OS;immune indexes;EORTC QLQ-C30 V3.0;DCR Study Design: Single arm

| 2683387 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data